Anastrozole Structural Formula (3cd04ed6 7c5a 4c4a 9955 Ee40839dfea0 01)
Anastrozole Tablet, Coated
Product Images NDC 68001-155
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Anastrozole (NDC 68001-155). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (3cd04ed6 7c5a 4c4a 9955 Ee40839dfea0 02)
This appears to be a graph showing Disease-free survival in months for two different treatments - tamodfen and anastrozole. The graph shows the proportion of patients alive and free of disease over time (in months). The x-axis shows the months, whereas the y-axis shows the proportion of patients alive and disease-free. However, there is some missing information and unclear characters in the text which make it difficult to interpret the graph fully.*
Figure 2 (3cd04ed6 7c5a 4c4a 9955 Ee40839dfea0 03)
This is a chart displaying the proportion of patients who were alive and free of disease during a randomized treatment. Two drugs were tested, tmodfen and amoxfen, and the chart shows the disease-free survival in months. The number of patients who were still at risk is shown on the right, organized by treatment (anastrozole vs anasromole) and time period.*
Figure 3 (3cd04ed6 7c5a 4c4a 9955 Ee40839dfea0 04)
This text provides a graph (Figure 3) of the Disease-Free Survival Kaplan Meier Survival Curve for all Patients Randomized to Anastrozole or Tamoxifen Monotherapy in the ATAC Trial. The graph shows the proportion of event-free months from 0 to 114 months, with randomized treatment (anastrozole and tamoxifen) labeled on the horizontal axis and the time to event (months) labeled on the vertical axis. The number of patients at risk is shown for each treatment category. The vertical axis has been truncated for the improved clarity of the Kaplan-Meier curves.*
Figure 4 (3cd04ed6 7c5a 4c4a 9955 Ee40839dfea0 05)
This figure (Figure 4) represents the Kaplan-Meier curves for disease-free survival in the hormone receptor-positive subpopulation of patients who were enrolled in the ATAC Trial and randomized to receive either anastrozole or tamoxifen monotherapy. The Kaplan-Meier curves are truncated to improve the clarity of the graph. The results are presented as a function of time to event in months, and the number of patients at risk are also reported.*
Figure 5 (3cd04ed6 7c5a 4c4a 9955 Ee40839dfea0 06)
This is a graph representing the time to progression in months for randomized treatment of two drugs - Anastrozole and Tamoxifen. The x-axis shows the months from 0 to 32 and the y-axis represents the number of patients at risk. The graph shows that Anastrozole is more effective than Tamoxifen in reducing the progression of the disease. However, no additional information is available.*
Figure 6 (3cd04ed6 7c5a 4c4a 9955 Ee40839dfea0 07)
This is a graph showing the time to progression in months for randomized treatment with anastrozole and tamoxifen. The x-axis shows the number of months and the y-axis shows the proportion not progressing. The graph is divided into two sections, one for randomized treatment with anastrozole and the other for tamoxifen. The data shows that anastrozole has a higher proportion not progressing than tamoxifen.*
Anastrozole Tablets 1mg 30ct Rev 09-17 (Anastrozole Tablets 1mg 30 Tablets Rev 0913)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
